Shares of genetic-testing company Invitae (NYSE: NVTA) rose over 13% today on an upbeat day for the stock market. The S&P 500 rose over 1.5% as investors cheered plans by some countries and U.S. states to soon begin reopening parts of their economies. While the broad economic damage caused by the coronavirus pandemic might take quarters or years to repair, the genetic testing industry might experience a faster recovery.

Invitae Corporation (NYSE: NVTA) today announced the closing of its underwritten public offering of 20,444,444 shares of its common stock, including 2,666,666 shares sold pursuant to the exercise in full of the underwriters' option to purchase additional shares, at the public offering price of $9.00 per share. As a result of the underwriters' option exercise, the aggregate gross proceeds to Invitae from the offering, before deducting underwriting discounts and commissions and other offering expenses, was approximately $184.0 million.

SAN FRANCISCO , May 7, 2020 /CNW/ -- Invitae (NVTA), a leader in medical genetics, today announced the expansion of online ordering for its high-quality medical genetic tests to Canada . Through the service, Canadians can access genetic testing recommended in early pregnancy as well as cancer risk assessments using telehealth guidance and kits that can be shipped to and from home. The service provides easier access to the same high-quality, medical genetic testing that experts use and trust worldwide during a time when healthcare visits are being delayed and wait times to see clinicians are growing.

Invitae (NVTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Invitae (NYSE: NVTA), a leading medical genetics company today announced new tools to help obstetrician/gynecologists, oncologists, genetic counselors and other clinicians who order genetic tests via telemedicine for women and couples early in pregnancy and for patients with cancer. Invitae's advanced clinical chatbot, Gia, provides an end-to-end telemedicine genetic testing framework that helps identify patients who need germline genetic testing.

Axovant Gene Therapies Ltd., a clinical-stage company developing innovative gene therapies for neurological diseases, today announced its collaboration with Invitae, a leading medical genetics company, in the Detect Lysosomal Storage Diseases (“Detect”) program to facilitate faster diagnoses for children with lysosomal storage disorders (“LSDs”), including GM1 gangliosidosis and GM2 gangliosidosis, also known as Tay-Sachs/Sandhoff disease. LSDs are progressive, multi-system, inherited metabolic diseases associated with premature death, and genetic testing is a crucial first step to arriving at a diagnosis.

(Bloomberg) -- U.K. retail sales dropped in April by the most in at least a quarter of a century, according to industry figures that outline the impact of the shutdown on stores.The British Retail Consortium said total sales fell 19.1% in April from a year earlier, the most since its monitor began in 1995. In a further sign of the damage done by the lockdown, a Barclaycard measure of consumer spending fell 36.5% last month.On the consortium’s like-for-like measure, which excludes temporarily closed stores, sales were up 5.7% in April. But most of that growth came from online shopping, which surged almost 60%.Online demand was driven by entertainment products and home-related goods, with computing equipment, household gadgets, toys and baby equipment performing strongly, according to the report. Clothing experienced a significant decline.Figures due later on Wednesday are forecast to show the U.K. economy shrank in the first quarter, reflecting the imposition of virus-related restrictions. The slump is likely to deepen this quarter, and the government is extending aid programs to help support workers and businesses.All British retailers have been affected by the lockdown. Even grocers and other shops deemed essential that have been allowed to continue operating have had to absorb higher costs as they implement social distancing and other measures.Under PressurePrimark, the value clothing chain owned by Associated British Foods Plc, has said the closure of all its shops is costing 650 million pounds ($800 million) of lost revenue a month. Marks & Spencer Group Plc has cut its dividend to preserve cash and weather the crisis. Next Plc reported a 41% plunge in full-price sales in the quarter ended April 25 and said business would remain under pressure for the rest of the year.Nearly all retailers have withdrawn financial guidance for the year.The lockdown has been “catastrophic” for retailers, the consultancy group BDO LLP said last week, adding that even the strongest online sales ever wouldn’t be able to offset the impact. Consumer behavior has changed drastically during lockdown, and retailers will need to adapt as they start to reopen, according to Sophie Michael, head of retail and wholesale at BDO.“With such a significant amount of spend removed, retailers will be focusing on preserving cash, engaging their customers through online channels, and building operational efficiency,” Michael said.(Updates with detail on retailers starting in sixth paragraph)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

Invitae (NVTA) delivered earnings and revenue surprises of 4.76% and 3.45%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

The medical genetics company achieved record-high testing volume growth in Q1. But the COVID-19 outbreak began taking a toll late in the quarter.

Invitae wants to provide medical-grade genetic testing to the masses. Is the business ready for the first big test?

Invitae's (NVTA) genetic testing business is expected to have gained from expansion of biopharma partnerships in Q1.

Is (NVTA) Outperforming Other Medical Stocks This Year?

The company thinks a post-pandemic world will appreciate the need for genetic information more than before, but Invitae must navigate uncertainty in the meantime.

Zarchi Lwin pawned her only two gold bangles for $140 when the owner of the Myanmar factory where she sewed winter coats for British retailer Next Plc shut it down after orders dried up due to the coronavirus. "If I have a job and an income, I can pay for medical treatment for my mother," Zarchi Lwin, 29, told Reuters from the home she shares with her 56-year-old mother, who has lung disease, in a shanty town on the outskirts of Yangon. KGG, the factory where Zarchi Lwin worked, did not respond to requests for comment.

Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced financial and operating results for the first quarter ended March 31, 2020.

Q1 2020 Invitae Corp Earnings Call

Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it will report its first quarter 2020 financial results on Tuesday, May 5, 2020 and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights.

Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted that a US recession is imminent and US stocks will go down by at least 20% in the next 3-6 […]

Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that members of its management team will virtually present at the William Blair 40th Annual Growth Stock Conference on Thursday, June 11, 2020 at 9:20 a.m. Central / 7:20 a.m. Pacific.

Ladies and gentlemen, thank you for standing by and welcome to the Invitae's First Quarter 2020 Financial Results Conference Call. Joining us today are Sean George, our CEO; Shelly Guyer, our CFO; Lee Bandekgey, our COO; Bob Nussbaum, our Chief Commercial Officer (sic); and Katherine Stueland, our Chief Commercial Officer.